Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Sep
17
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
Sep
10
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
Aug
05
UCB’s HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
Jun
17
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
Jun
12
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Jun
11
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
Apr
03
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
Mar
19
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
Mar
12
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome